Actively Recruiting
Early Versus Delayed Treatment With Venetoclax and Obinutuzumab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Led by National Cancer Institute (NCI) · Updated on 2026-11-02
247
Participants Needed
633
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are comparing early versus delayed treatment using venetoclax and obinutuzumab in patients newly diagnosed with high-risk chronic lymphocytic leukemia CLL or small lymphocytic lymphoma SLL. This phase III trial aims to see if starting treatment before symptoms appear improves overall survival and other outcomes. Venetoclax is a BCL-2 inhibitor that may stop cancer cell growth, and obinutuzumab is a monoclonal antibody that may help the immune system attack cancer cells. Participants are randomly assigned to one of two groups one begins treatment early after meeting eligibility criteria, and the other starts treatment only after symptoms develop. Both groups receive obinutuzumab intravenously on specified days during the first six cycles and venetoclax orally daily during later cycles, with treatment repeated every 28 days for up to 12 cycles. During and after treatment, patients undergo CT scans, blood sample collections, and bone marrow biopsies. Participants are monitored for up to 10 years after treatment to assess overall survival, progression-free survival, response rates, safety, and quality of life using the FACT-Leukemia scale. Researchers collect various samples and data, including measurable residual disease status and biomarkers. Patient compliance and adverse events are also tracked to better understand the treatment effects and long-term outcomes.
CONDITIONS
Brief Title
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here